DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation

Information source: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Atrial Fibrillation

Intervention: Amiodarone (Drug); Propafenone (Drug); Sotalol (Drug)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Official(s) and/or principal investigator(s):
Yi-Gang Li, MD, Principal Investigator, Affiliation: Xinhua Hospital, Shanghai Jiaotong University School of Medicne

Overall contact:
Yi-Gang Li, MD, Phone: 13761318166, Email: drliyigang@outlook.com


The current evidences indicate that ~30% patients with sick sinus syndrome(SSS) would develop persistent atrial fibrillation (AF) after a long term pacing therapy. However, the accurate influence of antiarrhythmic drugs on the AF is still not well defined. The purpose of the study is to assess the therapeutic effects of various antiarrhythmic drugs (Amiodarone, Sotalol and Propafenone) on the long term management of AF in SSS patients with AF, including the reduced AF burden (duration and episodes) and persistent AF free survival rate. All patients will be followed up for 12 months.

Clinical Details

Official title: Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Average AF burden in minutes per day

Persistent AF free survival rate

Secondary outcome:

Left ventricular function

SF-36 health survey

comorbidity and mortality


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- at least 18 years old

- sick sinus syndrome with pacemaker Class I or Class IIa indication

- has a pacemaker which can provide the daily AF burden monitor record for at least

28 days

- has at AF record in the past 6 months, the valid AF record includes any of

1. at least one 30 seconds AF holter record 2. at least one 15 seconds 12-ECG record 3. at least 5 minutes long AF episodes record from pacemakers

- able and willing to give informed consent

Exclusion Criteria:

- will have cardiac surgery in the next 6 month or in the waiting list of heart


- NYHA Class III or IV

- LVEF <50%

- Reversible AF, such as AF caused by hyperthyroidism or severe postoperative atrial


- Persistence AF

- Expected life expectancy less than 1 year

- Planned to be pregnant or be in the feeding period in the next year

- Non-stable, decompensated heart failure

- Allergy to Amiodarone, Propafenone or Sotalol

- Cancer

- Clear liver damage ( ALT and/or AST > 2*normal limit)

- Patients with cardiogenic shock history

- Be in the treatment of Amiodarone for more than 3 months or less than 3 months with

Amiodarone wash out period less than 30 days

- Coronary artery disease (CHD), cardiomyopathy, severe valvular heart disease, severe

obstructive pulmonary disease (COPD), long QT syndrome

Locations and Contacts

Yi-Gang Li, MD, Phone: 13761318166, Email: drliyigang@outlook.com

Xinhua Hospital, Shanghai Jiao Tong University School of Medicne, Shanghai, Shanghai 200092, China; Not yet recruiting
Yi-Gang Li, MD, Principal Investigator
Additional Information

Related publications:


Zhou ZQ, Hu DY, Chen J, Zhang RH, Li KB, Zhao XL. [An epidemiological survey of atrial fibrillation in China]. Zhonghua Nei Ke Za Zhi. 2004 Jul;43(7):491-4. Chinese.

Siu CW, Jim MH, Zhang X, Chan YH, Pong V, Kwok J, Kung AW, Lau CP, Tse HF. Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced versus non-hyperthyroidism-induced persistent atrial fibrillation. Am J Cardiol. 2009 Feb 15;103(4):540-3. doi: 10.1016/j.amjcard.2008.10.019. Epub 2008 Dec 25.

Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005 May 5;352(18):1861-72.

Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagné P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000 Mar 30;342(13):913-20.

Pritchett EL, Page RL, Carlson M, Undesser K, Fava G; Rythmol Atrial Fibrillation Trial (RAFT) Investigators. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol. 2003 Oct 15;92(8):941-6.

Israel CW. Analysis of mode switching algorithms in dual chamber pacemakers. Pacing Clin Electrophysiol. 2002 Mar;25(3):380-93. Review.

Passman RS, Weinberg KM, Freher M, Denes P, Schaechter A, Goldberger JJ, Kadish AH. Accuracy of mode switch algorithms for detection of atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2004 Jul;15(7):773-7.

Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon S, Mairesse GH, Brandes A, Crystal E, Costantini O, Sandhu RK, Parkash R, Connolly SJ, Hohnloser SH, Healey JS; ASSERT Steering Committee and Investigators. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm. 2012 Aug;9(8):1241-6. doi: 10.1016/j.hrthm.2012.03.017. Epub 2012 Mar 20.

Nowak B, McMeekin J, Knops M, Wille B, Schröder E, Moro C, Oelher M, Castellanos E, Coutu B, Petersen B, Pfeil W, Kreuzer J; Stored EGM in PulsarMax II and Discovery II Study Group. Validation of dual-chamber pacemaker diagnostic data using dual-channel stored electrograms. Pacing Clin Electrophysiol. 2005 Jul;28(7):620-9.

Charles D. Swerdlow, Jeffrey M. Gillberg, Paul Khairy, Textbook, Clinical Cardiac Pacing, Defibrillation and Resynchronization Therapy, Chapter 3, Sensing and Detection, page 146.

Starting date: May 2014
Last updated: May 20, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017